High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. (Q33788303)

29 July 2017

High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. (English)

1 reference

29 July 2017

0 references

1 reference

Yuichiro Eguchi

1

1 reference

29 July 2017

Toshihiko Mizuta

2

1 reference

29 July 2017

Tsutomu Yasutake

3

1 reference

29 July 2017

Akitaka Hisatomi

4

1 reference

29 July 2017

Ryuichi Iwakiri

5

1 reference

29 July 2017

Iwata Ozaki

6

1 reference

29 July 2017

Kazuma Fujimoto

7

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

World Journal of Gastroenterology

29 July 2017

1 reference

29 July 2017

12

1 reference

29 July 2017

4

1 reference

29 July 2017

556-560

1 reference

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Leptin, leptin receptors and the control of body weight

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Classification of chronic hepatitis: diagnosis, grading and staging

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Positional cloning of the mouse obese gene and its human homologue

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Charting of daily weight pattern reinforces maintenance of weight reduction in moderately obese patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

4 July 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I4.556

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I4.556

Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I4.556

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I4.556

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I4.556

Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I4.556

Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I4.556

Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066087

Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation

30 October 2018

1 reference

12 December 2020

The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C

1 reference

12 December 2020

Tumor necrosis factor increases serum leptin levels in humans

1 reference

12 December 2020

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V12.I4.556

1 reference

29 July 2017

1 reference

29 July 2017

1 reference